Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) EBIT (2016 - 2025)

Historic EBIT for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to -$2.9 million.

  • Pharma's EBIT fell 6471.59% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.1 million, marking a year-over-year increase of 1319.18%. This contributed to the annual value of -$7.4 million for FY2025, which is 2400.49% up from last year.
  • Latest data reveals that Pharma reported EBIT of -$2.9 million as of Q3 2025, which was down 6471.59% from -$1.9 million recorded in Q2 2025.
  • Pharma's EBIT's 5-year high stood at -$1.4 million during Q1 2025, with a 5-year trough of -$6.5 million in Q1 2022.
  • Its 5-year average for EBIT is -$2.7 million, with a median of -$2.4 million in 2024.
  • As far as peak fluctuations go, Pharma's EBIT crashed by 15942.72% in 2021, and later surged by 4627.38% in 2024.
  • Quarter analysis of 5 years shows Pharma's EBIT stood at -$2.4 million in 2021, then increased by 4.49% to -$2.3 million in 2022, then crashed by 31.61% to -$3.0 million in 2023, then soared by 37.36% to -$1.9 million in 2024, then tumbled by 54.37% to -$2.9 million in 2025.
  • Its last three reported values are -$2.9 million in Q3 2025, -$1.9 million for Q2 2025, and -$1.4 million during Q1 2025.